de Smet M D, Stark-Vancs V, Kohler D R, Smith J, Wittes R, Nussenblatt R B
Clinical Immunology Section, National Eye Institute, Bethesda, MD 20892-1858, USA.
Am J Ophthalmol. 1996 Apr;121(4):442-4. doi: 10.1016/s0002-9394(14)70444-1.
To determine if adequate intraocular levels of methotrexate are achieved after intravenous administration.
After intravenous administration, methotrexate levels were determined in the serum, the anterior chamber, and the cerebrospinal fluids of a patient with recurrent ocular lymphoma. A fluorescence polarization immunoassay was used to make the determinations.
At seven hours into a 24-hour intravenous infusion, methotrexate was at cytotoxic level in all samples. At 74 hours, cytotoxic levels were present only in the aqueous humor.
Sustained cytotoxic ocular methotrexate levels are achievable after systemic administration.
确定静脉给药后甲氨蝶呤在眼内是否能达到足够的水平。
对一名复发性眼淋巴瘤患者静脉给药后，测定其血清、前房和脑脊液中甲氨蝶呤的水平。采用荧光偏振免疫分析法进行测定。
在24小时静脉输注7小时时，所有样本中甲氨蝶呤均处于细胞毒性水平。在74小时时，仅房水中存在细胞毒性水平。
全身给药后可实现眼内甲氨蝶呤持续的细胞毒性水平。
